Telbivudine in the treatment of chronic hepatitis B: Experience in HIV type-1-infected patients naive for antiretroviral therapy

Antiviral Therapy

Volumn 14, Issue 6, 2009, Pages 869-872

  Milazzo, Laura ^a   Caramma, Ilaria ^a   Lai, Alessia ^a   Violin, Michela ^a   De Maddalena, Chiara ^a   Cesari, Miriam ^a   Galli, Massimo ^a   Balotta, Claudia ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PEGINTERFERON ALPHA2A; RNA DIRECTED DNA POLYMERASE; TELBIVUDINE; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG EXPOSURE; FOLLOW UP; GENETIC RESISTANCE; HEPATITIS B; HEPATITIS B VIRUS; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MIXED INFECTION; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MALE; NUCLEOSIDES; PYRIMIDINONES;

EID: 72049112033     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1303     Document Type: Article

References (18)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
2. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-88. (Pubitemid 351228130)
3. Dieterich DT. Special considerations and treatment of patients with HBV-HIV coinfection. Antivir Ther 2007; 12 Suppl 3:H43-H51.
4. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302-1306. (Pubitemid 29510871)
5. Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudineresistant hepatitis B and HIV-1. J Hepatol 2006; 44:62-67. (Pubitemid 41772517)
6. Standring DN, Bridges EG, Placidi L, et al. Antiviral betal- nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001; 12 Suppl 1:119-129.
7. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129:528-536. (Pubitemid 41096641)
8. Bryant ML, Bridges EG, Placidi l, et al. Antiviral l-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001; 45:229-235. (Pubitemid 32039120)
9. Avila C, Karwowska S, Lai C, Evans T. Telbivudine has no in vitro activity against laboratory and clinical HIV-1, including 5 clades and drug-resistant clinical isolates. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 813b.
10. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008; 48:353-367.
11. Balotta C, Violin M, Monno l, et al. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure. J Acquir Immune Defic Syndr 2000; 24:232-240. (Pubitemid 30748927)
12. De Maddalena C, Giambelli C, Tanzi E, et al. High level of genetic heterogeneity in S and P genes of genotype D hepatitis B virus. Virology 2007; 365:113-124. (Pubitemid 46907230)
13. Delaugerre C, Marcelin AG, Thibault V, et al. Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIVcoinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 2002; 46:1586-1588. (Pubitemid 34415353)
14. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007; 356:2614-2621.
15. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE Trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136:486-495.
16. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147:745-754. (Pubitemid 351664439)
17. Wu ZG, Yan WM, Zou Y, Wang HW, Ning Q. Telbivudine preserves Th1 cytokine and inhibit Th2 cytokine production in MHV-3 induced viral hepatitis model. Hepatol Int 2009; 3:43.
18. Low E, Cox A, Atkins M, Nelson M. Telbivudine has activity against HIV-1. AIDS 2009; 23:546-547.